Hypereosinophilic syndrome [2] (multiple letters)

New England Journal of Medicine

Volumn 348, Issue 26, 2003, Pages 2687-

  Roufosse, Florence E ^a   Goldman, Michel ^a   Cogan, Elie ^a   Gilliland, D Gary ^b   Stone, Richard M ^c   Coutre, Steven E ^d  

^a ERASME HOSPITAL   (Belgium)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; GENE PRODUCT; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FIP1L1; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INTERLEUKIN 5; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CLONAL VARIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FUSION GENE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; CELL CLONE; CHROMOSOME DELETION; GENETIC RECOMBINATION; GENETICS; IMMUNOLOGY; NOTE; SECRETION;

CHROMOSOME DELETION; CLONE CELLS; ENZYME INHIBITORS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; PHENOTYPE; PIPERAZINES; PYRIMIDINES; RECOMBINATION, GENETIC; T-LYMPHOCYTES;

EID: 0038309770     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200306263482616     Document Type: Letter

References (0)